Sea Cucumber in Wound Care and Biomedical Applications: The Science Behind an Ancient Claim

There is a moment in the life of a sea cucumber that no other commercially traded marine animal experiences. When threatened by a predator it cannot escape, the animal contracts its body wall, ruptures its own cloacal tissue, and expels its internal organs — respiratory trees, digestive tract, gonads — into the water. The predator is distracted or entangled. The sea cucumber, now hollow, moves away. And then, over the course of two to eight weeks, it regenerates the expelled organs entirely from the cells that remain.

This capacity for complete visceral regeneration is not a metaphor. It is a documented biological process that operates through mechanisms — growth factor upregulation, extracellular matrix remodeling, cell migration and proliferation, angiogenesis — that are precisely the mechanisms that determine the quality and speed of wound healing in mammalian tissue. The sea cucumber does not merely survive evisceration. It rebuilds itself from the inside, using the same molecular toolkit that wound care researchers have spent decades trying to harness for human therapeutic applications.

Traditional medicine systems across Asia and the Pacific have used sea cucumber preparations for wound treatment for centuries, without knowing why they worked. The scientific literature of the past two decades has been progressively answering that question — documenting the specific compounds, the specific mechanisms, and the specific clinical and preclinical outcomes that explain the biological rationale behind an ancient claim.

The Wound Healing Process and Where Sea Cucumber Bioactives Intervene

Wound healing in mammalian tissue proceeds through four overlapping phases: hemostasis, the initial clotting response that stops bleeding; inflammation, the immune response that clears pathogens and damaged tissue; proliferation, the phase in which new tissue is synthesized and blood vessels are formed; and remodeling, the final phase in which the new tissue matures and strengthens over weeks to months.

Sea cucumber-derived bioactive compounds have been documented to intervene at multiple points in this sequence. A scoping review published in Compendium of Oral Science (Universiti Teknologi MARA, 2024), assessing clinical trials and in vivo studies of sea cucumber as a therapeutic agent for wound healing, identified the primary bioactive compound classes responsible for documented wound healing activity as fucosylated chondroitin sulfate, triterpene glycosides, glycosaminoglycans, collagen and collagen-derived peptides, polysaccharides, and phospholipids. Each operates through specific molecular mechanisms at specific phases of the healing process.

Fucosylated Chondroitin Sulfate: The Compound That Exists Only in Sea Cucumber

Fucosylated chondroitin sulfate, abbreviated FuCS or fCS, is a polysaccharide that is structurally unique to sea cucumbers among all known biological sources. As documented in a review published in Carbohydrate Polymers (Elsevier), FuCS is a characteristic compound found nowhere else but in the echinoderm sea cucumber. Holothurian glycosaminoglycan is composed of a common polysaccharide backbone found in mammalian chondroitin sulfates, but the uronic acid residue bears an unusual sulfated fucosyl branch O-linked to its carbon-3 position, a structural feature absent from all mammalian chondroitin sulfates. This holothurian glycosaminoglycan has demonstrated various biological activities including antithrombotic, antitumor, immunostimulatory, wound healing, hypolipidemic, anti-hyperglycemia, angiogenesis, and antibacterial effects.

The structural uniqueness of FuCS has direct implications for its wound healing mechanism. The fucosyl branches on the polysaccharide backbone enable interactions with specific growth factor receptors and extracellular matrix proteins that conventional chondroitin sulfate from mammalian sources cannot replicate. Research has confirmed that FuCS promotes angiogenesis — the formation of new blood vessels in healing tissue — through interactions with vascular endothelial growth factor (VEGF) that depend specifically on the fucosylated structure. Angiogenesis is a rate-limiting step in wound healing: tissue cannot complete the proliferative phase without an adequate blood supply to deliver oxygen and nutrients to regenerating cells.

The species-specificity of FuCS structure is a sourcing consideration with direct commercial implications for pharmaceutical and biomedical manufacturers. Different sea cucumber species produce FuCS with different sulfation patterns on the fucose branches, and research has confirmed that these structural differences affect biological activity. For manufacturers requiring FuCS with specific structural characteristics — for example, a particular anti-inflammatory activity profile or a specific angiogenesis-promoting capacity — species authentication of the raw material is a functional requirement, not merely a documentation formality.

Collagen and Collagen-Derived Peptides: The Tissue Architecture Support

Sea cucumber collagen's role in wound healing has been discussed in the context of cosmetics applications in article 34 of this series. In the biomedical wound care context, the same collagen properties that make it attractive for skincare formulations operate at a more fundamental level of tissue repair.

Research published in Frontiers in Marine Science (2022) reviewing in vivo and clinical studies of sea cucumber-derived bioactives from 2012 to 2021 documented that sea cucumber-derived compounds demonstrated wound healing properties including the promotion of wound healing in a diabetic mouse model. Small molecule oligopeptides isolated from sea cucumber at dose groups of 0.25, 0.5, and 1 gram per kilogram of body weight all demonstrated wound sites with less bruising and swelling, and higher vascularization, collagen deposition, and epithelialization than the diabetic model control group.

The diabetic wound model finding is clinically significant beyond the specific test system. Diabetic wounds represent one of the most clinically challenging wound categories, characterized by impaired angiogenesis, chronic inflammation, and deficient collagen synthesis that collectively prevent the normal progression through the healing phases. A bioactive that promotes healing in diabetic wound conditions is a candidate ingredient for a category of wound care products with substantial unmet clinical need. Research published in Biomedical Materials (IOP Publishing, 2025) on sea cucumber protein paste applied to mouse skin wound models confirmed that collagen expression increased by 13.89% and 15.12% in low-dose and high-dose treatment groups compared with controls on day 14, with new blood vessel formation and fibroblast generation documented in the treatment groups.

The bone healing application of sea cucumber collagen represents an adjacent biomedical context. Research on hydroxyapatite composites incorporating collagen from Stichopus hermanni, one of the Indonesian commercial species profiled in article 25, prepared as bone graft substitutes documented good biocompatibility in rat models. Stichopus hermanni is an Indonesian species with commercially available collagen that has been specifically studied for biomedical applications in peer-reviewed literature — a convergence of commercial accessibility and documented biomedical utility that is unusual in the broader marine biomaterial landscape.

Tetrapeptides and Small Peptides: The Molecular Precision Tools

Recent research has moved beyond crude extract activity to identify specific peptide sequences responsible for documented wound healing effects. Research published in ScienceDirect (2023) on tetrapeptides isolated from sea cucumber body wall identified two specific peptide sequences that promote wound healing through multiple mechanisms: the two peptides significantly contribute to the healing of skin wounds by promoting re-epithelialization, collagen and lipid regeneration for skin appendage remodeling, and enhancing angiogenesis both in vitro and in vivo.

The identification of specific peptide sequences responsible for wound healing activity has direct implications for pharmaceutical product development. Once an active sequence is characterized, it can in principle be synthesized without requiring biological extraction — though the cost economics of synthesis versus extraction determine which production pathway is commercially viable at scale. For ingredient manufacturers, the characterization of specific active sequences from sea cucumber body wall peptides provides the molecular-level evidence that regulatory submissions for therapeutic wound care products require, moving beyond the "standardized extract" characterization that has historically been the ceiling of evidence for traditional medicine-derived wound care ingredients.

Research published in Marine Drugs (MDPI, 2025) on small peptide fractions from Isostichopus badionotus body wall and purified collagen documented, for the first time, the isolation and in vitro testing of 1-3 kDa peptide fractions from this species for wound healing capacity, finding that low-molecular-weight peptides from body wall proteins have wound-healing properties whose potency varies by species, growth environment, age, and season. This species-and-condition variability finding has direct implications for raw material sourcing specifications: for pharmaceutical applications requiring consistent wound healing bioactivity, specification of species, geographic origin, and seasonal harvest window is necessary to ensure batch-to-batch consistency in active compound content.

The Regeneration Biology Connection: Why Sea Cucumber Is Different

The wound healing bioactivity of sea cucumber is not coincidental. It reflects the same biological systems that enable the animal's extraordinary regenerative capacity. Research on the gene expression patterns during regeneration after evisceration in sea cucumbers has identified the molecular pathways involved: extracellular matrix remodeling genes, growth factor pathways including FGF and Wnt signaling, and immune regulatory pathways that manage the transition from inflammatory to proliferative phases of regeneration.

These pathways are not unique to sea cucumber — they are conserved evolutionary mechanisms shared with vertebrate wound healing. What is unique to sea cucumber is the efficiency with which these pathways operate, and the concentration of the bioactive compounds that regulate them in the body wall tissue. An animal that regenerates complete visceral organs from residual cells does so using the same molecular toolkit that mammalian wound healing requires, operating at an efficiency that evolution has optimized over hundreds of millions of years.

For biomedical researchers and ingredient manufacturers, this biological framing transforms sea cucumber from a traditional medicine ingredient with anecdotal history into a validated source of compounds with documented mechanistic rationale for their wound healing activity. The traditional claim and the scientific evidence are not in tension. They converge on the same biology from different starting points.

Current Research Gaps and Future Development Directions

Despite the volume of in vitro and in vivo research documenting wound healing activity from sea cucumber-derived compounds, the clinical evidence base in human subjects remains limited. The 2022 Frontiers in Marine Science review of sea cucumber in vivo and clinical studies from 2012 to 2021 noted explicitly that while the majority of studies were conducted in vitro, the number of in vivo and evidence-based human clinical studies was limited. This gap between preclinical and clinical evidence is the primary constraint on pharmaceutical development of sea cucumber wound care applications.

For ingredient manufacturers and pharmaceutical developers evaluating sea cucumber as a raw material for wound care product development, this gap defines both the opportunity and the development pathway. The preclinical evidence is sufficiently strong across multiple compound classes and multiple wound models to support investment in clinical development. The clinical evidence, when it is generated, will determine whether specific sea cucumber-derived ingredients can achieve regulatory status as wound care actives in regulated markets rather than remaining confined to cosmetic or nutraceutical categories.

Sepanjang's direct sourcing from Indonesian waters across commercially significant sea cucumber species provides access to the raw material base for manufacturers pursuing both nutraceutical and biomedical applications of sea cucumber-derived compounds. Our team is available to discuss species availability, product forms, and documentation requirements for wound care and biomedical sourcing applications.

__________________________________________________________________________________________

Sepanjang — Indonesia's Specialty Ocean Products Co. Sourcing high-quality sea cucumber directly from Indonesian waters for over 20 years.

PT Sepanjang Laut Nusantara is an Indonesia's Specialty Ocean Products Co. specializing in Sea Cucumber, Seaweed, Abalone, and Seashell from Indonesia — for domestic and international B2B markets.

SEPANJANG

PRODUCT

Sea Cucumbers
Seaweed
Abalone
Seashell

© 2025 PT Sepanjang Laut Nusantara. All rights reserved.